New York Life Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

New York Life Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.5M	Buy	43,218 +5,149	+14%	+$2.28M	0.15%	120
2026 Q1	$17M	Buy	38,069 +1,251	+3%	+$583K	0.14%	132
2025 Q4	$16.7M	Sell	36,818 -614	-2%	-$265K	0.14%	131
2025 Q3	$14.7M	Sell	37,432 -1,468	-4%	-$614K	0.13%	140
2025 Q2	$17.3M	Buy	38,900 +294	+0.8%	+$135K	0.16%	122
2025 Q1	$18.7M	Sell	38,606 -454	-1%	-$212K	0.19%	111
2024 Q4	$15.7M	Buy	39,060 +383	+1%	+$178K	0.15%	122
2024 Q3	$18M	Sell	38,677 -789	-2%	-$379K	0.17%	113
2024 Q2	$18.5M	Buy	39,466 +401	+1%	+$174K	0.19%	113
2024 Q1	$16.3M	Sell	39,065 -1,344	-3%	-$568K	0.16%	118
2023 Q4	$16.4M	Sell	40,409 -7,342	-15%	-$2.71M	0.17%	115
2023 Q3	$16.6M	Sell	47,751 -1,444	-3%	-$505K	0.18%	111
2023 Q2	$17.3M	Sell	49,195 -235	-0.5%	-$79.2K	0.18%	117
2023 Q1	$15.6M	Sell	49,430 -3,076	-6%	-$923K	0.17%	127
2022 Q4	$15.2M	Sell	52,506 -242	-0.5%	-$73.8K	0.17%	138
2022 Q3	$15.3M	Sell	52,748 -792	-1%	-$228K	0.18%	121
2022 Q2	$15.1M	Buy	+53,540	New	+$14.3M	0.18%	122

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

New York Life Investment Management's VRTX Position: Q2 2026 in Review

New York Life Investment Management increased its Vertex Pharmaceuticals (VRTX) stake by 14% in Q2 2026, buying an estimated $2.28M and bringing the position to 43,218 shares worth $21.5M. The position accounts for 0.15% of the portfolio, ranked #120.

New York Life Investment Management first reported a position in VRTX in Q2 2022 and has held it in 17 quarters since. 1,298 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

New York Life Investment Management held 43,218 shares of Vertex Pharmaceuticals worth $21.5M as of Q2 2026.
New York Life Investment Management bought 5,149 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.28M.
Vertex Pharmaceuticals made up 0.15% of New York Life Investment Management's portfolio in Q2 2026, its #120 holding.
New York Life Investment Management first reported a position in Vertex Pharmaceuticals in Q2 2022 and has held it in 17 quarters since.
1,298 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on New York Life Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.